Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for EIK1001 in Stage 4 NSCLC. The expected timing is based on the latest available company guidance and may change.
5/3/26:- TeLuRide-005 Ph2 in 1L Stage 4 NSCLC completed enrollment; updated ORR/DCR data presented at ASCO 2026. TeLuRide-008 Ph2/3 FPD expected 2H 2026. 07/20/26:- ESMO 2026 to present TeLuRide-005 squamous cohort and pooled results; TeLuRide-008 trial highlighted. 07/27/26:- TeLuRide-008 Ph2/3 first patient dosed (NCT07365319). 08/13/26:- TeLuRide-005 full combination data will be presented October 26, 2026. TeLuRide-008 Ph2/3 is ongoing.
Verification
Confirm timing and program details against the company announcement or filing.